IRVINE, Calif., May 27, 2015 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a global leader in the aesthetic medical device marketplace, introduces UltraShape®, an innovative and fast way to lose stubborn belly fat.
TV Star And Mother Of Four Turns To UltraShape To Get Rid Of Stubborn Fat
UltraShape's newest devotee, Larsa Pippen, Real Housewives of Miami Alumni, wife of six-time world champion NBA star Scottie Pippen, and fitness enthusiast, talked about her UltraShape experience during a May 6 press conference in New York City. Larsa said of the treatment, "UltraShape gives me more confidence. I eat well and exercise regularly, but as a mom of four, there are certain areas that are resistant to all my efforts. With UltraShape, the inches are disappearing; I lost 1.5 inches and I love my results so much that even my mom and my friends are doing it, too." Even those who are fully committed to living a healthy lifestyle and who maintain meticulous beauty routines still see results with UltraShape. Pippen further detailed, "UltraShape delivers fast results without pain or downtime."
As the perfect complement to a regular diet and exercise regimen, UltraShape targets extra abdominal fat that just won't budge, despite a healthy lifestyle. An easy, painless, and faster alternative to traditional body shaping treatments, UltraShape can help consumers drop up to two sizes in just three 45-minute sessions.* Treatments take less than an hour and patients can go right back to their normal activities, making it an ideal lunch hour treatment. First results may be visible as early as two weeks post treatment. Finally, there's a way to achieve a flatter stomach, without the agony of countless sit-ups and crunches.
As the first and only FDA-approved non-invasive body contouring system that uses focused, pulsed ultrasound energy to target and instantly destroy stubborn fat, UltraShape offers measurable fat reduction to the abdominal area without the risks and downtime associated with other fat reduction procedures. "UltraShape is the fastest non-invasive fat reduction technology; nothing non-invasive works faster," states Leslie Baumann, MD. "UltraShape's patented technology delivers ultrasound energy with extraordinary accuracy, allowing us to target and destroy fat cells immediately. Unlike traditional ultrasound technology, UltraShape distributes energy in pulses rather than in a single continuous delivery, which can be painful. The result is a quick, safe and comfortable treatment experience without the lumps, bumps or soreness associated with other non-invasive fat reduction treatments."
"UltraShape uses ultrasound technology that was perfected in 10 years of research and developed by world leading scientists and doctors to non-invasively destruct fat without any damage to surrounding tissue," states Shimon Eckhouse, Ph.D., Chairman of the Board of Directors for Syneron Candela.
Research conducted by Syneron Candela found that 60 percent of women are dissatisfied with their abdominal area, and 52 percent would consider having a non-invasive procedure. "Our goal with UltraShape is to revolutionize the way men and women achieve a flatter abdominal region by offering technologically advanced, non-invasive and comfortable options to reduce stubborn abdominal fat," says Ilan Nacasch, Chief Brand Officer at Syneron Candela.
To learn more about UltraShape, visit: www.ultrashape.com
About Syneron Candela
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch, and has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, Profound and elos Plus.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit http://www.syneron-candela.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including product efficacy, market acceptance of new products, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and in the filings that Syneron Medical makes with the SEC, and other factors beyond the Company's control. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from those expressed or implied by these forward-looking statements. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
*Individual results may vary.
 Syneron data on file